Assessing Arena Pharmaceutical Belviq Sales And The Impact Of TV Ads
Arena Investors Need To Watch Contrave Launch Closely
By Spencer Osborne : Orexigen (NASDAQ: OREX ) announced today that the anti-obesity drug Contrave is now available for prescriptions in the United States. Orexigen's marketing partner Takeda has set up several ways that consumers can save money on their weight-loss medication as well as monitor ...
anti-obesity drug to be approved by the FDA in over 10 years. This is following the approval of Belviq ( Arena Pharmaceuticals (NASDAQ: ARNA )) and Qsymia (Vivus (NASDAQ: VVUS )) back in 2012. Following its approval, OREX stock has tanked
By Spencer Osborne : Sales of the Arena Pharmaceuticals (NASDAQ: ARNA ) anti-obesity pill Belviq seem to be seeing some impacts of seasonality with ups and downs as the Fall weeks progress. This
toward healthcare there is no denying that Wall Street will be there as well. When launched, Orexigen will join Arena (NASDAQ: ARNA ) and Vivus (NASDAQ: VVUS ) as one of three companies with FDA approved anti-obesity drugs on the market. Other players
impressive sales numbers, though sales in the most recent years are not the same as they were at their peak. The news surrounding Chantix surfaces at a time when Arena Pharmaceuticals (NASDAQ: ARNA ) and its marketing partner Complete Story »
By Spencer Osborne : Sales of Belviq, the anti-obesity drug from Arena Pharmaceuticals (NASDAQ: ARNA ) were up this week and now pacing slightly ahead of the "guidance" pace I outlined many months ago. When you look at my weekly
Top gainers, as of 5:15 p.m.: UNIS +15.7% . RBCN +4.4% . HERO +4.2% . FBR +2.8% . OTCQB:GSAT +2.5%. Top losers, as of 5:15 p.m.: TILE -23.0% . GPRO -2.7% . SAVE -2.4% . ARNA -2.3% . BKW -2.3% . Post your comment!
that all of the hype and potential of the market size fizzled when Vivus (NASDAQ: VVUS ) launched Qsymia and Arena (NASDAQ: ARNA ) launched Belviq. It was not long after the launch of these drugs that the market came to realize that the anti-obesity sector